Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

flex, Thanks for the reply.

As I said, I'd be thrilled with that sort of payout but am increasingly doubtful as to whether it is achievable.

The Barclay's opinion just posted says it pretty clearly. To get beyond their $6 target (IMO that translates to a $10-$12 b/o today, $18 if we get gigantic '113, '788 news, and an ONYX type deal), we'd need to support this company out through 2018. I'm not sure what else remains to be possibly sold off for more cash except for actual molecules, or gulp, stock (if they can find takers). There just won't be enough cash. With 1500 ramping into new trials, that's probably more costly than all the Pona and '113 trials before it, combined. And those other trials are still running, losing us $40M-$50 a quarter. All the study news that LUNA posts is very good research, and the fact it has done nothing for the pps is sobering.

So Q4 US, '113 and '788 news in a few weeks (I think), that will tell us a lot about whatever PP has to say, whether folly or fortune.